Početna › Leukemija › Illinois › Chicago
Kliničke studije za Leukemija u gradu Chicago, IL
16 studija za Leukemija traži sudionike na lokacijama u gradu Chicago i okolici (unutar oko 30 milja). Otvorite studiju da biste vidjeli tko se može priključiti i kako kontaktirati tim studije.
Službeni tekst studije (engleski)
Tražite sudionike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
U tijeku regrutacijaFaza 1/2
- The University of Chicago Medical Center, Chicago
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
U tijeku regrutacijaFaza 3
- Research Site, Chicago
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
U tijeku regrutacijaFaza 1/2
- University of Chicago, Chicago
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
U tijeku regrutacijaFaza 1
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
U tijeku regrutacijaFaza 2
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
U tijeku regrutacijaFaza 1/2
- Research Site, Chicago
Mosaic Trial for Stem Cell Transplant Recipients
U tijeku regrutacija
- Northwestern University Feinberg School of Medicine, Chicago
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
U tijeku regrutacijaFaza 2
- University of Chicago Medical Center, Chicago
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
U tijeku regrutacijaOpažajna studija
- Lurie Children's Hospital-Chicago, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
U tijeku regrutacijaFaza 1/2
- University of Illinois at Chicago Cancer Center, Chicago
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
U tijeku regrutacijaFaza 1
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia
U tijeku regrutacija
- UChicago Medicine Comprehensive Cancer Center, Chicago
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
U tijeku regrutacijaFaza 1/2
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
U tijeku regrutacija
- University of Chicago Comprehensive Cancer Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
U tijeku regrutacijaOpažajna studija
- Massive Bio SYNERGY-AI site, Chicago
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
U tijeku regrutacijaFaza 1
- Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
Studije za Leukemija u drugim gradovima
- Houston, TX28 studija
- Boston, MA25 studija
- New York City, NY19 studija
- Los Angeles, CA16 studija
- Durham, NC13 studija
- Baldwin Park, CA12 studija
- Columbus, OH12 studija
- Nashville, TN12 studija
- Philadelphia, PA12 studija
- Milwaukee, WI11 studija
- Atlanta, GA11 studija
- Seattle, WA11 studija
Ostale studije u gradu Chicago
- Nemikrocelularni karcinom pluća61 studija
- Rak dojke58 studija
- Rak (sve vrste)51 studija
- Metastatski karcinom45 studija
- Rak prostate45 studija
- Debljina41 studija
- Rak pluća41 studija
- Rak jajnika36 studija
- Moždani udar34 studija
- Kolorektalni rak33 studija
- Srčano zatajenje31 studija
- Prekomjerna tjelesna masa28 studija
Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.